It will be administered using a needle-free applicator as opposed to traditional syringes. The applicator, called "PharmaJet", will be sold at ₹93 per dose, excluding GST.
“The pricing has been decided in consultation with the Government of India," the Gujarat-based firm said.
The vaccine received emergency use authorisation from India's drug regulator on 20 August, and is the first one cleared for inoculation of those aged 12 years and above in the country.
However, a comprehensive programme for paediatric immunisation, including developing a priority list of comorbidities, is still being worked out by the NTAGI (National Technical Advisory Group on Immunisation) for the launch of ZyCoV-D and Covaxin.
“We are happy to support the government’s vaccination programme with ZyCoV-D," said Dr Sharvil Patel, the company's managing director, after receiving the Centre's order.
“The needle-free application of the vaccination, we hope, will motivate many more to vaccinate and safeguard themselves from Covid-19, especially children and young adults in the age group of 12 to 18 years," added Patel.